Teladoc (NYSE: TDOC) disclosed regarding the Livongo Health (NASDAQ: LVGO) deal:

On October 29, 2020, Teladoc Health, Inc. (“Teladoc”) held a special meeting of its stockholders (the “Special Meeting”). At the Special Meeting, based on preliminary voting results, Teladoc’s stockholders voted to (a) approve the issuance of shares of Teladoc common stock to the stockholders of Livongo Health, Inc. (“Livongo”), pursuant to the Agreement and Plan of Merger, dated as of August 5, 2020 (the “Merger Agreement”), by and among Teladoc, Livongo and Tempranillo Merger Sub, Inc. (the “Teladoc Share Issuance Proposal”), (b) adopt an amendment to the certificate of incorporation of Teladoc (the “Teladoc Charter Amendment Proposal”) and (c) approve the adjournment of the Special Meeting to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve the Teladoc Share Issuance Proposal and the Teladoc Charter Amendment Proposal or to ensure that any supplement or amendment to Teladoc’s joint proxy statement/prospectus is timely provided to Teladoc stockholders.

Based on the results of the Special Meeting, subject to the satisfaction or waiver of the remaining closing conditions under the Merger Agreement, the transactions contemplated by the Merger Agreement are expected to be consummated on October 30, 2020.